You’re sitting in the peds ED, and just about done with the 10th URI you’ve seen all day. You’ve got the sniffles from those cute coughing babies, and you’ve been getting through the day on just those “free” pedialyte icee’s and apple juice, so you’re a bit delirious. You start thinking that there are a lot of cute things that have spots. Let’s see – you think of giraffes, dalmations, Sully from Monster’s Inc…and the kid you see right in front of you. Wait, what? A non-URI? You’re about to sign up for this one before the next booger-filled nose calls you away.

A 6 year-old previously healthy boy comes into the Peds ED with his mother complaining of a new rash on his legs for the last 4 days. He is afebrile, and other vital signs unremarkable. The rash appears like large red circles, slightly raised; they are palpable, don’t blanch, and are present from his feet superiorly to below his knees.

It started bilaterally on his feet and has been growing upward since then. You also notice he has swollen ankles bilaterally and both appear slightly erythematous and are warm to touch. He says this has also been going on for the last 4 days, but thinks it started after he tripped and fell at school a few days back. He has had abdominal pain as well, without any nausea or vomiting. He doesn’t have any history of recent travel, camping, and no known bug bites. 

1. What is your differential?
  • Henoch-Schonlein Purpura (HSP)
  • Thrombotic Thrombocytopenic Purpura (TTP)
  • Immune Thrombocytopenic Purpura (ITP)
  • Juvenile Idiopathic Arthritis (JIA)/Juvenile Rheumatoid Arthritis (JRA)
  • Meningococcemia
  • Bacterial Endocarditis
  • Diffuse Intravascular Coagulation (DIC)
2. What tests would you like to order?

  • CBC, CMP, coagulation profile, urinalysis
  • ESR/CRP, +/- IgA level
  • Consider rheumatologic tests including C3/C4 levels, dsDNA, and ANA
3. What is Henoch-Schonlein Purpura?

HSP is a small vessel vasculitis, closely related to IgA vasculitis, and it is the most common vasculitis in childhood. Its pathogenesis is related to hypersensitivity, IgA deposition, and neutrophilic damage to the vasculature. HSP can affect the small blood vessels of the skin, GI tract, joints, kidneys, and CNS.

It is very similar to a leukocytoclastic vasculitis, which is a small vessel vasculitis that can affect many areas of the body. There are many causes for leukocytoclastic vasculitis, including medications, malignancy, collagen-vascular diseases, and idiopathic causes. What is important to remember, is they both commonly present with palpable purpura.

4. Who does HSP affect?

More than 75% of those affected are less than 10 years old, and the peak age of incidence is four to six years. Males are affected more than females in a 2:1 ratio. Of note, HSP can also affect adults and is often more severe when it does so.

5. How does HSP usually present?

The most common hallmark of HSP is palpable, cutaneous purpura, most often affecting the legs and buttocks. The classic HSP presentation involves palpable purpura and joint pain in a child, with abdominal pain or hematuria. It can also present with vomiting, bloody stools, and scrotal edema. The rash usually lasts about 3 weeks.

6. What are some important diagnoses to consider, and how can you differentiate them from HSP?
  • ITP/TTP/HUS: These present with purpura (usually considered non-palpable) but also present with thrombocytopenia, whereas the platelet count in HSP is generally normal to elevated.
  • DIC: Platelet count is reduced in DIC, and again usually normal to elevated in HSP. In addition, DIC is more common in the setting of severe sepsis or trauma, where HSP does not typically present with clinical deterioration.
  • Bacterial Endocarditis/Meningococcemia: A purpuric rash can be present in these disorders as well, often resulting from DIC; however, a careful history and physical can exclude these etiologies based on clinical features. You can always refer to Dr. Alfonso’s post on Duke Criteria for endocarditis for a refresher: So Bored I Began to Murmur
  • Systemic Vasculitis: Disorders like Wegener’s glomerulonephritis, microscopic polyangitis, or mixed cyroglobulinemia can present with renal damage, glomerulonephritis, and skin lesions. While this might not be figured out in the ED, it’s important to consider the whole clinical picture. Labwork such as C3/C4 levels, cyroglobulin levels, and rheumatoid factor may be considered to start your patient’s workup.
  • Rheumatologic Disorders: It’s important to consider SLE, JIA/JRA, and other rheumatologic diseases, as it may help with treatment decisions and future follow-up/management. Consider concurrent symptoms, previous occurrences, and labwork such as C3/C4, ANA and ds-DNA to help form a better clinical picture.
  • Acute Abdomen: Given its GI involvement, HSP may mimic an abdominal emergency. Although rare, complications like intussusception can be seen in 2-6% of cases. Also rare are perforation and bowel ischemia. Consider the whole clinical picture, and remember most abdominal pain in HSP is benign. Consider further imaging such as ultrasound if indicated.
7. What is the most appropriate ED management?

The mainstay of HSP treatment is supportive. This means ensuring the patient, or child, is well hydrated with their pain controlled and watching out for abdominal and renal complications – worsening pain, hematuria, proteinuria, and acute renal failure. If you suspect any drug-related causes, discontinue those agents. Acetaminophen or NSAIDS can be used for minor complications like mild abdominal pain, arthralgia, or swelling, but avoid NSAIDS in cases with renal complications.

8. What is the most appropriate long term management for this patient?

Renal involvement is the most serious and common long-term complication, and monitoring for development of hypertension is needed to ensure adequate treatment and consultation if indicated. Urinalysis and blood pressure monitoring should be continued for up to 6 months after presentation, even if essentially normal during the first visit.

9. What is the disposition for this patient?

In self-limiting cases of HSP, the child can often be discharged home with close follow-up with instructions for adequate hydration and pain control. Although there are no real criteria, consider admission in patients with severe abdominal pain or vomiting, acute renal complications and need for monitoring, or if the diagnosis is unclear.

10. What is the role of corticosteroids in this condition?

The use of corticosteroids and other immunosuppressive therapy for HSP is controversial and debated. A meta-analysis done by Weiss et. Al in 2007(1) showed a reduction in time to resolution of abdominal pain and a significant reduction in the odds of developing chronic renal disease with early use. However, another study has shown no significant reduction in delayed nephritis in children with HSP treated with corticosteroids.(2) The lack of RCTs makes it difficult to offer a clear clinical recommendation.

While the “when and how” to use corticosteroids remains unclear, the general opinion seems to be to use corticosteroids if complications are present such as renal disease, severe abdominal pain, intussusception, or bowel perforation.(3, 4)

References:

  1. Weiss et al. Effects of Corticosteroids on HSP: A Systematic Review. Pediatrics. November 2007; 120(5):1079-1087
  2. Saulsbury, F.T. Corticosteroid therapy does not prevent nephritis in Henoch-Schonlein Purpura. Pediatric Nephrology 1993; 7(69) doi:10.1007/BF00861574
  3. Reid-Adam J. Henoch-Schonlein Purpura. Pediatrics in Review. October 2014; 35(10)447-9
  4. Reamy, et al. Henoch-Schonlein Purpura. American Family Physician October 2009; 80(7):697-704.
  5. Haemel A, et al. Cutaneous Small Vessel Vasculitis. Vasculitis. Oxford University Press 2008: 350-355
  6. Ronkainen et al. Early prednisone therapy in Henoch-Schonlein Purpura – a randomized, double blind, placebo controlled trial. Journal of Pediatrics. August 2006; 149(2): 241-7
  7. Henoch-Schonlein Purpura [Internet]. Practice Essentials, Background, Pathophysiology. 2017 [cited 2017 May 11];Available from: http://emedicine.medscape.com/article/984105-overview
The following two tabs change content below.

Delna

PGY3 Clinical Monster in Training

Delna

PGY3 Clinical Monster in Training

0 Comments

Leave a Reply

Avatar placeholder

Your email address will not be published. Required fields are marked *

%d bloggers like this: